Skip to Content

Alger Health Sciences A AHSAX

Medalist Rating as of | See Alger Investment Hub
  • NAV / 1-Day Return 21.82  /  +0.55 %
  • Total Assets 115.3 Mil
  • Adj. Expense Ratio
    1.050%
  • Expense Ratio 1.050%
  • Distribution Fee Level Low
  • Share Class Type Front Load
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 1,000
  • Status Open
  • TTM Yield
  • Turnover 306%

USD | NAV as of Feb 23, 2024 | 1-Day Return as of Feb 23, 2024, 11:10 PM GMT+0

Morningstar’s Analysis AHSAX

Will AHSAX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Alger Health Sciences A earns a Morningstar Medalist Rating of Neutral with strength in areas such as People offset by weaker spots such as Process.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings AHSAX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 50.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

UnitedHealth Group Inc

10.33 11.3 Mil
Healthcare

Boston Scientific Corp

5.25 5.7 Mil
Healthcare

Eli Lilly and Co

4.58 5.0 Mil
Healthcare

Regeneron Pharmaceuticals Inc

4.48 4.9 Mil
Healthcare

Cash

4.48 4.9 Mil
Cash and Equivalents

Vertex Pharmaceuticals Inc

4.47 4.9 Mil
Healthcare

Amgen Inc

4.44 4.9 Mil
Healthcare

Cardinal Health Inc

4.42 4.8 Mil
Healthcare

Molina Healthcare Inc

4.11 4.5 Mil
Healthcare

Humana Inc

3.96 4.3 Mil
Healthcare